Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Circadian Gene Polymorphisms Associated with Breast Cancer Susceptibility.

Lesicka M, Jabłońska E, Wieczorek E, Pepłońska B, Gromadzińska J, Seroczyńska B, Kalinowski L, Skokowski J, Reszka E.

Int J Mol Sci. 2019 Nov 14;20(22). pii: E5704. doi: 10.3390/ijms20225704.

2.

A different methylation profile of circadian genes promoter in breast cancer patients according to clinicopathological features.

Lesicka M, Jabłońska E, Wieczorek E, Seroczyńska B, Kalinowski L, Skokowski J, Reszka E.

Chronobiol Int. 2019 Aug;36(8):1103-1114. doi: 10.1080/07420528.2019.1617732. Epub 2019 Jun 9.

PMID:
31179760
3.

Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients.

Markiewicz A, Topa J, Nagel A, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ.

Cancers (Basel). 2019 Jan 9;11(1). pii: E59. doi: 10.3390/cancers11010059.

4.

Altered circadian genes expression in breast cancer tissue according to the clinical characteristics.

Lesicka M, Jabłońska E, Wieczorek E, Seroczyńska B, Siekierzycka A, Skokowski J, Kalinowski L, Wąsowicz W, Reszka E.

PLoS One. 2018 Jun 29;13(6):e0199622. doi: 10.1371/journal.pone.0199622. eCollection 2018.

5.

CD271+, CXCR7+, CXCR4+, and CD133+ Stem/Progenitor Cells and Clinical Characteristics of Acute Ischemic Stroke Patients.

Gójska-Grymajło A, Zieliński M, Gąsecki D, Kowalczyk K, Kwarciany M, Seroczyńska B, Nyka WM.

Neuromolecular Med. 2018 Sep;20(3):301-311. doi: 10.1007/s12017-018-8494-x. Epub 2018 May 9.

6.

Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients.

Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ.

Transl Oncol. 2018 Jun;11(3):722-731. doi: 10.1016/j.tranon.2018.03.006. Epub 2018 Apr 16.

7.

CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.

Czapiewski P, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Sejda A, Szade J, Wiewiora C, Biernat W, Żaczek A.

Pol J Pathol. 2015 Sep;66(3):269-75.

8.

Differentiation of high-risk stage I and II colon tumors based on evaluation of CAV1 gene expression.

Kitowska A, Wesserling M, Seroczynska B, Szutowicz A, Ronowska A, Peksa R, Pawelczyk T.

J Surg Oncol. 2015 Sep;112(4):408-14. doi: 10.1002/jso.23995. Epub 2015 Aug 6.

PMID:
26251082
9.

Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.

Ronowicz A, Janaszak-Jasiecka A, Skokowski J, Madanecki P, Bartoszewski R, Bałut M, Seroczyńska B, Kochan K, Bogdan A, Butkus M, Pęksa R, Ratajska M, Kuźniacka A, Wasąg B, Gucwa M, Krzyżanowski M, Jaśkiewicz J, Jankowski Z, Forsberg L, Ochocka JR, Limon J, Crowley MR, Buckley PG, Messiaen L, Dumanski JP, Piotrowski A.

Hum Mutat. 2015 Nov;36(11):1088-99. doi: 10.1002/humu.22845. Epub 2015 Aug 14.

PMID:
26219265
10.

Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Markiewicz A, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Majewska H, Szade J, Żaczek AJ.

Am J Transl Res. 2014 Nov 22;6(6):793-808. eCollection 2014.

11.

Gel electrophoretic separation of proteins from cultured neuroendocrine tumor cell lines.

Miękus N, Olędzka I, Plenis A, Woźniak Z, Lewczuk A, Koszałka P, Seroczyńska B, Bączek T.

Mol Med Rep. 2015 Feb;11(2):1407-15. doi: 10.3892/mmr.2014.2864. Epub 2014 Nov 5.

PMID:
25373396
12.

Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.

Markiewicz A, Książkiewicz M, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Szade J, Żaczek AJ.

PLoS One. 2014 Apr 7;9(4):e93901. doi: 10.1371/journal.pone.0093901. eCollection 2014.

13.

Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer.

Markiewicz A, Książkiewicz M, Seroczyńska B, Skokowski J, Szade J, Wełnicka-Jaśkiewicz M, Zaczek AJ.

Cancers (Basel). 2013 Nov 8;5(4):1485-503. doi: 10.3390/cancers5041485.

14.

Chemometric evaluation of urinary steroid hormone levels as potential biomarkers of neuroendocrine tumors.

Plenis A, Miękus N, Olędzka I, Bączek T, Lewczuk A, Woźniak Z, Koszałka P, Seroczyńska B, Skokowski J.

Molecules. 2013 Oct 16;18(10):12857-76. doi: 10.3390/molecules181012857.

15.

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer.

Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W, Zaczek AJ.

J Transl Med. 2012 Nov 19;10:226. doi: 10.1186/1479-5876-10-226.

16.

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T, Olszewski WP, Szade J, Rhone P, Welnicka-Jaskiewicz M, Jassem J.

Oncologist. 2012;17(10):1246-55. doi: 10.1634/theoncologist.2012-0023. Epub 2012 Aug 7.

17.

CD73 expression as a potential marker of good prognosis in breast carcinoma.

Supernat A, Markiewicz A, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade J, Czapiewski P, Biernat W, Zaczek A.

Appl Immunohistochem Mol Morphol. 2012 Mar;20(2):103-7.

PMID:
22553809
18.

Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

Zaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczyńska B, Skokowski J, Szade J, Czapiewski P, Biernat W, Wełnicka-Jaśkiewicz M, Jassem J.

Pathol Oncol Res. 2012 Oct;18(4):885-94. Epub 2012 Mar 18.

Supplemental Content

Loading ...
Support Center